NexCure

Executive Summary

NexCure is a preclinical-stage biotechnology company based in Cambridge, MA, dedicated to developing novel small molecule therapies for oncology. The company leverages a proprietary drug discovery platform designed to target historically undruggable pathways in cancer, addressing significant unmet needs in both solid tumors and hematological malignancies. Founded in 2017, NexCure's pipeline is in early preclinical development, with no disclosed candidates yet. The company's innovative approach holds promise for breakthrough treatments, but it remains in a high-risk, early-stage phase typical of many biotech startups. Key upcoming milestones include initial preclinical data readouts and potential IND-enabling studies, which will be critical for advancing its pipeline and attracting partnerships or funding.

Upcoming Catalysts (preview)

• Q2 2026Preclinical Proof-of-Concept Data for Lead Candidate50% success
• Q4 2026IND Filing for Lead Program30% success
• Q3 2026Series A or Partnership Announcement40% success